Zahraa I. J. Shubber

Zahraa I. J. Shubber

Auto-generated profile, based on publicly available information

Zahraa I. J. Shubber

DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, COLLEGE OF PHARMACY, AL-MUSTAQBAL UNIVERSITY, HILLAH, BABILON, IRAQ

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2025 in Wiadomości Lekarskie
Verified
Journal Article
Open access
PDF file
ZSZahraa I. J. Shubber
Zahraa I. J. Shubber
QFQayssar Joudah Fadheel
Qayssar Joudah Fadheel
Aim: Aims: This study was performed to investigate the potential nephroprotective effect of Tangeretin on bilateral renal I/R injury in male rats. Material and methods: Materials and methods: Forty male rats were split into four groups of ten (sham, control, DMSO, and Tangeretin). The sham group underwent a median laparotomy under anaesthesia without inducing ischemia/reperfusion; the control group underwent clamping for thirty minutes on the bilateral renal artery, followed by two hours of reperfusion; the vehicle group received DMSO one hour before induction of ischemia; and the Tangeretin group received 5 mg/kg of Tangeretin one hour before ischemia. Biochemical parameters (KIM1, IL-1β, and TNF-α, F2-isoprostane, GSH, and caspase-3) were measured using an ELISA approach. Furthermore, histological alterations were examined, and the Notch/Jagged1 signalling pathway was assessed using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Results: Results: Tangeretin pre-treatment reduced kidney damage molecules (KIM1, IL-1β, and TNF-α, F2-isoprostane, GSH, and caspase-3) while increasing antioxidant indicators and decreasing inflammatory and apoptotic markers. Improving histological outcomes and significantly decreasing Notch1 and Jagged-1 gene expression in kidney tissues during renal ischemia/reperfusion injury. Conclusions: Conclusion: Tangeretin has significant nephroprotective advantages in renal IRI by decreasing the Notch pathway and exhibiting anti-apoptotic, antioxidant, and anti-inflammatory properties.

30 December 2025 in Wiadomości Lekarskie
Verified
Journal Article
Open access
PDF file
ZSZahraa I. J. Shubber
Zahraa I. J. Shubber
QFQayssar Joudah Fadheel
Qayssar Joudah Fadheel
Aim: Aims: This study was performed to investigate the potential nephroprotective effect of Dibenzazepin on bilateral renal I/R injury in male rats. Material and methods: Materials and methods: Forty male rats were divided into four groups’ n=10: sham, control, DMSO, and DBZ, the sham group had a median laparotomy under anaesthesia without induction of ischemia/reperfusion; the control group underwent clamping for thirty minutes on the bilateral renal artery, after that two hours of reperfusion; the vehicle group received DMSO one hour before induction of ischemia; and the DBZ group received 2 mg/kg of DBZ one hour before ischemia. Biochemical parameters (Kidney injury molecules KIM1, IL-1β, TNF-α, F2-isoprostane, GSH, and caspase-3) were assessed by ELISA technique. Furthermore, histological changes were investigated, and the Notch signalling pathway was evaluated using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Results: Results: IRI caused a significant increase in renal tissues of (Kidney injury molecules KIM1, IL-1β, TNF-α, F2-isoprostane, and caspase-3) with significant decreased the level of GSH, DBZ pre-treated mitigated these effects by significant enhancing antioxidant markers and decreased inflammatory and apoptotic markers. Improving histological results and significant decrease the Notch1 and Jagged-1 gene expression in kidney tissues after renal ischemia/reperfusion damage. Conclusions: Conclusion: DBZ (γ-secretase inhibitor) has considerable nephroprotective benefits in renal IRI via inhibiting the Notch pathway, anti-apoptotic, antioxidant, and anti-inflammatory effect.

30 March 2026 in Journal of Biomedicine and Biochemistry
Verified
Journal Article
Open access
PDF file
RMRusul Ahmed Mohammed
Rusul Ahmed Mohammed
NHNada Khazal K. Hindi
Nada Khazal K. Hindi
Mustafa Hussein MohammedMustafa Hussein Mohammed
Mustafa Hussein Mohammed
ZSZahraa I. J. Shubber
Zahraa I. J. Shubber
AGAbdolmajid Ghasemian
Abdolmajid Ghasemian
Acute Myeloid Leukemia comprises a heterogeneous group of clonal disorders that result from the abnormal accumulation of immature myeloid cells within the bone marrow and peripheral blood. This study aims to detect Advances in the Molecular Pathogenesis of Acute Myeloid Leukemia. This has been elucidated by recent molecular studies that identified crucial mutations in FLT3, NPM1, and DNMT3A genes and epigenetic changes that contribute to leukemogenesis. Deregulated pathways besides PI3K/AKT and MAPK have also asserted themselves in disease progression and resistance to therapy. Hence, the review presents an extensive discussion of contemporary molecular perspectives of AML pathogenesis and their relevance to diagnosis and treatment. The rise in targeted therapies and precision medicine thus paints a promising clinical picture for a better prognosis. Knowledge of the biological compromise unleashed by mutations in genes and their interplay with the bone marrow microenvironment is key to forging newer therapies.

5 May 2024 in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Verified
Journal Article
Closed access
FAFatima Adnan Alzubaidi
Fatima Adnan Alzubaidi
EOEnass Najem Oubaid
Enass Najem Oubaid
ZSZahraa I. J. Shubber
Zahraa I. J. Shubber
HAHussam Al-Humadi
Hussam Al-Humadi
RARafal J. Al-Saigh
Rafal J. Al-Saigh
Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has been documented all over the world. Currently, limited evidence exists concerning the protec¬tion afforded by the COVID-19 vaccination against reinfection with SARS-CoV-2. This case-control study was per¬formed in order to assess the association between COVID-19 vaccination and SARS-CoV-2 reinfection in the Babil Province; the study used an electronic questionnaire. The infected patients were 115 (aged ≥18 years) and were confirmed by a positive PCR and/or a CT scan, they were either fully vaccinated or not with a second dose of a (Pfizer, AstraZeneca, or Sinopharm) vaccine before the reinfection date, and they were compared with 300 control partici¬pants. The study’s findings revealed that the unvaccinated individuals had 4.5 times the odds of reinfection compared to those who were fully vaccinated, without preference for the manufacturer of the vaccine. The conclusion suggests that getting fully vaccinated against COVID-19 can significantly reduce the likelihood of reinfection, can enhance overall protection, and can minimize the risk of future infections.